World's Best Scientists 2026 revealed!
David Dingli

David Dingli

D-Index & Metrics

Medicine

D-Index
97
Citations
35614
World Ranking
9263
National Ranking
4781

Overview

David Dingli is affiliated with the Mayo Clinic in the United States and has contributed extensively to medical research, particularly within hematology and oncology. Their work spans several subfields, including hematology, molecular biology, oncology, genetics, and immunology, with a significant focus on disorders related to blood and immune system function.

The main fields of study for Dingli include:

  • Medicine
  • Biochemistry, Genetics and Molecular Biology

Key subfields of research encompass:

  • Hematology
  • Molecular Biology
  • Oncology
  • Genetics
  • Immunology

Dingli's primary research topics involve:

  • Multiple Myeloma Research and Treatments
  • Amyloidosis: Diagnosis, Treatment, Outcomes
  • Protein Degradation and Inhibitors
  • CAR-T cell therapy research
  • Chronic Lymphocytic Leukemia Research
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Complement system in diseases

The scientist has published numerous articles in high-impact journals, with frequent contributions to venues such as:

  • Blood
  • Clinical Lymphoma Myeloma & Leukemia
  • Blood Cancer Journal
  • Journal of Clinical Oncology
  • Leukemia

Noteworthy recent papers by David Dingli include:

  • "Systemic amyloidosis from A (AA) to T (ATTR): a review" (2020), Journal of Internal Medicine
  • "Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response" (2020), Blood Cancer Journal
  • "Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities" (2020), Blood Advances
  • "Mortality trends in multiple myeloma after the introduction of novel therapies in the United States" (2021), Leukemia
  • "A simple additive staging system for newly diagnosed multiple myeloma" (2022), Blood Cancer Journal

Dingli has collaborated extensively with other researchers, with frequent co-authors including:

  • Prashant Kapoor
  • Rahma Warsame
  • Taxiarchis Kourelis
  • Morie A. Gertz
  • Shaji Kumar

Best Publications

  • Improved survival in multiple myeloma and the impact of novel therapies

    Shaji K. Kumar;S. Vincent Rajkumar;Angela Dispenzieri;Martha Q. Lacy

  • Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients

    S K Kumar;A Dispenzieri;M Q Lacy;M A Gertz

  • Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain Measurements

    Shaji Kumar;Angela Dispenzieri;Martha Q. Lacy;Suzanne R. Hayman

  • Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines

    Shaji K. Kumar;Joseph R. Mikhael;Francis K. Buadi;David Dingli

  • Oral selinexor-dexamethasone for triple-class refractory multiple myeloma

    Ajai Chari;Dan T Vogl;Maria Gavriatopoulou;Ajay K Nooka

  • Genetic progression and the waiting time to cancer

    Niko Beerenwinkel;Tibor Antal;David Dingli;Arne Traulsen

  • Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma

    Martha Q. Lacy;Suzanne R. Hayman;Morie A. Gertz;Angela Dispenzieri

  • Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter

    David Dingli;Kah Whye Peng;Mary E. Harvey;Philip R. Greipp

  • Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death.

    Eli Muchtar;Morie A. Gertz;Shaji K. Kumar;Martha Q. Lacy

  • Mayo Clinic Consensus Statement for the Use of Bisphosphonates in Multiple Myeloma

    Martha Q. Lacy;Angela Dispenzieri;Morie A. Gertz;Philip R. Greipp

  • Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma.

    Grzegorz S. Nowakowski;Thomas E. Witzig;David Dingli;Michal J. Tracz

  • Remission of Disseminated Cancer After Systemic Oncolytic Virotherapy

    Stephen J. Russell;Mark J. Federspiel;Kah Whye Peng;Caili Tong

  • Successful Therapy Must Eradicate Cancer Stem Cells

    David Dingli;David Dingli;Franziska Michor

  • Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease.

    Martha Q. Lacy;Jacob B. Allred;Morie A. Gertz;Suzanne R. Hayman

  • Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics.

    Shaji Kumar;Rafael Fonseca;Rhett P. Ketterling;Angela Dispenzieri

  • A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy

    A K Stewart;P L Bergsagel;P R Greipp;A Dispenzieri

  • Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)

    M Q Lacy;S R Hayman;M A Gertz;K D Short

  • The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndrome.

    Anita D'Souza;Suzanne R. Hayman;Francis Buadi;Michelle Mauermann

  • Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria.

    Arjun Lakshman;S. Vincent Rajkumar;Francis K. Buadi;Moritz Binder

  • Unexplained Pulmonary Hypertension in Chronic Myeloproliferative Disorders

    David Dingli;James P. Utz;Michael J. Krowka;Ann L. Oberg

Frequent Co-Authors

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a career in Medicine and healthcare offers a wide variety of online degree options and alternative career pathways. For registered nurses aiming to advance their qualifications, enrolling in the cheapest rn to bsn program online is a cost-effective way to increase earning potential and career opportunities.

Non-nursing graduates interested in nursing can explore direct entry nurse practitioner programs for non-nurses online. These accelerated pathways allow those without a nursing background to move directly into advanced nursing roles, meeting workforce demands quickly.

For those seeking institutions with flexible admission criteria, researching direct admit nursing programs can simplify entry into the field. Additionally, individuals interested in healthcare administration and support roles may consider enrolling in medical billing and coding schools online to pursue non-clinical jobs with strong growth potential.

These varied options make it easier for students to find an educational path that fits their goals, budget, and lifestyle when considering a future in medicine or allied health professions in the USA.

Best Scientists Citing David Dingli

Trending Scientists

Recently Published Articles